ABSTRACT
OBJECTIVE: to assess the effectiveness of oral trazodone 150 mg/d for treatment of erectile dysfunction. PATIENTS AND METHODS: A double-blind, placebo controlled, multicentre trial. A run-in period of two weeks was followed by four weeks of medication. Evaluation was done by patients diary, a questionnaire and Rigiscan nightly penile tumescence and rigidity (NPTR) measurements in the second and sixth week of the trial. RESULTS: 69 patients were randomised, two patients never returned for follow-up, nine patients stopped the medication due to side-effects, so 58 patients are evaluable for effect assessment. Half of the patients suffered psychogenic impotence. There was no significant difference in the subjective results of trazodone compared to placebo. Side effects occurred more often with the use of trazodone, but this was not statistically significant. CONCLUSION: In a group of patients, that was not selected on the basis of the etiology of the erectile dysfunction, nor selected on the duration of the complaint, the efficacy of trazodone 150 mg/d, could not be shown.
Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Erectile Dysfunction/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Trazodone/therapeutic use , Double-Blind Method , Erectile Dysfunction/psychology , Humans , Male , Placebos , Trazodone/administration & dosage , Trazodone/adverse effects , Treatment OutcomeABSTRACT
AIM OF THE STUDY: to evaluate the feasibility of a self-injection programme for impotence with a combination of 10 micrograms prostaglandine E1 (PGE1) and 0.5 mg phentolamine. METHOD: follow-up at outpatients department with history taking, physical examination and questionnaires of 58 patients using this combination. Many patients could compare this drug combination with previously used drugs for intracavernous use. RESULTS: 42 patients started regular use. After a follow-up of 14 months, 26 are still on the programme. Drug related problems encountered: 10 patients reported insufficient erectile response, five patients have had priapism, four patients experienced severe pain, one patient developed fibrosis. CONCLUSION: the combination of PGE1 and phentolamine is very effective. The complication rate is comparable with those reported from PGE1 alone and from papaverine with phentolamine.
Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Alprostadil/therapeutic use , Erectile Dysfunction/drug therapy , Penile Erection/drug effects , Phentolamine/therapeutic use , Adrenergic alpha-Antagonists/administration & dosage , Adult , Aged , Alprostadil/administration & dosage , Drug Combinations , Erectile Dysfunction/physiopathology , Humans , Injections , Male , Middle Aged , Papaverine/administration & dosage , Papaverine/therapeutic use , Penis , Phentolamine/administration & dosage , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic useABSTRACT
We report the successful treatment of an abscess in the corpus cavernosum of a paraplegic man on intracavernous papaverine injection therapy by means of percutaneous aspiration and intravenous antibiotics. After 3 months of intracavernous pharmacotherapy the patient experienced good erections again and only minimal fibrosis could be found on palpation.